Risk of VTE in the Vienna Cancer and Thrombosis Cohort according to baseline MPV. The study included 99 patients with pancreatic cancer only with MPV below and above 10.8 fL. Competing risk analysis incorporating death from any cause except due to fatal VTE was the competing end point. (Figure adapted with permission from Riedl et al.³² )